- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Expires: February 28, 2011 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * WOOD JULIANNA R	2. Issuer Name and Ticker or Trading Symbol ONYX PHARMACEUTICALS INC [ ONXX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                      _____ 10% Owner __ X __ Officer (give title below)      _____ Other (specify below) VP, Public Affairs
(Last)          (First)          (Middle) C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE.	3. Date of Earliest Transaction (MM/DD/YYYY) 3/31/2011
(Street) SOUTH SAN FRANCISCO, CA 94080 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _ X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	3/31/2011		A		2500   (1)	A	$0.00	10953	D
Common Stock	3/31/2011		A		8000   (2)	A	$0.00	118953	D
Common Stock	3/31/2011		F		428   (3)	D	$35.18	18525	D
Common Stock	4/1/2011		S		1078   (4)	D	$35.02	17447	D
Common Stock								200	I	Childrens' Trust

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.18	3/31/2011		A		17500		(5)	3/31/2021	Common Stock	17500	$0.00	17500	D

Explanation of Responses:
( 1)	Represents a restricted stock award granted to the reporting person. The restricted stock award vests annually over 3 years.
( 2)	Represents restricted stock units granted to the reporting person. Each restricted stock unit represents a right to receive one share of the issuer's common stock. The restricted stock unit vests upon the meeting of certain milestones.
( 3)	Payment of exercise price or tax liability by delivering or withholding securities incident to receipt, exercise or vesting of a security issued in accordance with Rule 16b-3.
( 4)	Shares sold pursuant to a 10b5-1 plan.
( 5)	12.5% of the shares subject to the option become exercisable 6 months following the date of grant. The remaining shares become exercisable in equal monthly installments over the following 42 months for a total vesting schedule of 48 months.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
WOOD JULIANNA R C/O ONYX PHARMACEUTICALS, INC. 249 EAST GRAND AVE. SOUTH SAN FRANCISCO, CA 94080			VP, Public Affairs

Signatures
/s/ Matthew K. Fust, Attorney-in-fact		4/4/2011
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.